Medical Management of Hidradenitis Suppurativa with Non-Biologic Therapy: What's New?

Am J Clin Dermatol. 2022 Mar;23(2):167-176. doi: 10.1007/s40257-021-00667-8. Epub 2022 Jan 6.

Abstract

Hidradenitis suppurativa (HS) is a severe chronic relapsing inflammatory disorder of the hair follicle unit that can cause painful abscesses, nodules, tunnels, and tracts in intertriginous parts of the body. The disease can often result in disfigurement and adversely impact patient quality of life. The management of HS has expanded significantly over the past decade to include multiple modalities, including topical therapies, systemic therapies (non-biologics and biologics), surgical therapies, lifestyle changes, and management of comorbidities. Management can often be clinically challenging and may involve the combination of medical and surgical approaches for optimal results. The purpose of this review is to present an update on non-biologic and non-interventional modalities published in 2019-2021 in the clinical management of HS. With emerging therapies, ongoing clinical trials, and heightened awareness about HS, there is hope that new treatment options will revolutionize the management of patients suffering from HS.

Publication types

  • Review

MeSH terms

  • Abscess
  • Comorbidity
  • Hair Follicle
  • Hidradenitis Suppurativa* / drug therapy
  • Hidradenitis Suppurativa* / therapy
  • Humans
  • Quality of Life